New Antibiotics for Staphylococcus aureus Infection : An Update from the World Association of Infectious Diseases and Immunological Disorders (WAidid) and the Italian Society of Anti-Infective Therapy (SITA)
Esposito, Susanna (Pediatric Clinic. Pietro Barilla Children's Hospital. Department of Medicine and Surgery. University Hospital of Parma)
Blasi, Francesco (Ca' Granda Ospedale Maggiore Policlinico Milano)
Curtis, Nigel (Department of Infectious Diseases. The Royal Children's Hospital Melbourne)
Kaplan, Sheldon (Division of Infectious Diseases. Department of Pediatrics. Baylor College of Medicine)
Lazzarotto, Tiziana (IRCCS Azienda Ospedaliero-Universitaria di Bologna)
Meschiari, Marianna (Azienda Ospedaliero-Universitaria of Modena)
Mussini, Cristina (Azienda Ospedaliero-Universitaria of Modena)
Peghin, Maddalena (Infectious and Tropical Diseases Unit. Department of Medicine and Surgery. University of Insubria-ASST-Sette Laghi)
Rodrigo Gonzalo de Líria, Carlos (Institut Germans Trias i Pujol)
Vena, Antonio (IRCCS Ospedale Policlinico San Martino)
Principi, Nicola (Università degli Studi di Milano)
Bassetti, Matteo (IRCCS Ospedale Policlinico San Martino)
Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública

Fecha:	2023
Resumen:	Staphylococcus aureus is an extremely virulent pathogen that is capable of quickly evolving and developing antibiotic resistance. To overcome this problem, new antibiotics have been developed. Some of these have been licenced for use in clinical practice, mainly for the treatment of adults with acute skin and soft tissue infections, in addition to both community-acquired pneumonia (CAP) and nosocomial pneumonia (hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia). In this paper, the main characteristics and clinical use of new licenced anti-staphylococcal drugs have been discussed. In vitro studies have demonstrated that some new anti-staphylococcal antibiotics have better antimicrobial activity and, at least in certain cases, more favourable pharmacokinetic properties and higher safety and tolerability than the presently available anti-staphylococcal drugs. This suggests that they may have a potential use in reducing the risk of failure of S. aureus therapy. However, an in-depth analysis of microbiological and clinical studies carried out with these new drugs seems to indicate that further studies need to be conducted before the problem of resistance of S. aureus to the antibiotics available today can be completely solved. Considering the overall available research, the drugs that are active against S. aureus appear to present a great therapeutic opportunity for overcoming resistance to traditional therapy. There are advantages in the pharmacokinetic characteristics of some of these drugs and they have the potential to reduce hospital stays and economic costs associated with their use.
Nota:	Altres ajuts: World Association for Infectious Diseases and Immunological Disorders (WAidid; WAidid-2022-01).
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article de revisió ; recerca ; Versió publicada
Publicado en:	Antibiotics, Vol. 12 Núm. 4 (april 2023) , art. 742, ISSN 2079-6382

DOI: 10.3390/antibiotics12040742
PMID: 37107104

17 p, 367.8 KB

El registro aparece en las colecciones:
Documentos de investigación > Documentos de los grupos de investigación de la UAB > Centros y grupos de investigación (producción científica) > Ciencias de la salud y biociencias > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Artículos > Artículos de investigación
Artículos > Artículos publicados